| Trial ID: | L0105 |
| Source ID: | NCT02927314
|
| Associated Drug: |
CF102
|
| Title: |
A Study of the Efficacy and Safety of CF102 in the Treatment of Non-Alcoholic Fatty Liver Disease
|
| Acronym: |
--
|
| Status: |
Completed
|
| Study Results: |
No Results Available
|
| Results: |
--
|
| Conditions: |
Non-alcoholic Steatohepatitis (NASH)
|
| Interventions: |
Drug: CF102|Drug: Placebo
|
| Outcome Measures: |
Efficacy of CF102 as determined by change in serum alanine aminotransferase (ALT) levels|Efficacy of CF102 as determined by change in magnetic resonance imaging-determined hepatic steatosis|Body weight in subjects with NAFLD|Waist circumference in subjects with NAFLD|HDL cholesterol levels in subjects with NAFLD|Normalization of serum ALT levels in subjects with NAFLD|Serum aspartate aminotransaminase (AST) levels in subjects with NAFLD|Hemoglobin A1c levels and degree of insulin resistance|Pharmacokinetics (PK) of CF102 in this population|Peripheral blood expression of the A3 adenosine receptor (A3AR).|Nature, frequency, and severity of adverse events in this patient population
|
| Sponsor/Collaborators: |
Can-Fite BioPharma
|
| Gender: |
All
|
| Age: |
18 Years and older ?? (Adult, Older Adult)
|
| Phases: |
Phase 2
|
| Enrollment: |
60
|
| Study Type: |
Interventional
|
| Study Designs: |
Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment
|
| Start Date: |
November 27, 2017
|
| Completion Date: |
March 1, 2020
|
| Results First Posted: |
--
|
| Last Update Posted: |
March 17, 2020
|
| Locations: |
Can-Fite Investigational Site #318, Jerusalem, Israel|Can-Fite Investigational Site #319, Nazareth, Israel|Can-Fite Investigational Site #311, Petach Tikva, Israel
|
| URL: |
https://ClinicalTrials.gov/show/NCT02927314
|
